Clinical Trials on Multiple Sclerosis (MS) Relapsing Remitting
Total 3116 results
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Claudio GobbiBayerTerminatedRelapsing-remitting Multiple SclerosisSwitzerland
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.A.S, FranceCompletedMultiple Sclerosis, Relapsing, Remitting
-
Coordinación de Investigación en Salud, MexicoCompleted
-
NovartisCompletedEfficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (FREEDOMS)Relapsing-remitting Multiple SclerosisCanada, Australia, Israel, Belgium, Czech Republic, Finland, France, Germany, Greece, Lithuania, Netherlands, Poland, Russian Federation, Slovakia, South Africa, Sweden, Switzerland, Turkey, United Kingdom
-
Universita di VeronaCompletedRelapsing-remitting Multiple SclerosisItaly
-
University Hospital Inselspital, BernePharmaPart; Viollier AG, Basel, SwitzerlandCompletedRelapsing-remitting Multiple SclerosisSwitzerland
-
Cantonal Hospital of St. GallenUnknownRelapsing-Remitting Multiple SclerosisSwitzerland
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisFinland
-
NeurognosticsCompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisCzechia, Belgium
-
Institute for Clinical ResearchUnknownRelapsing-Remitting Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing Remitting Multiple Sclerosis RRMSGermany, Switzerland
-
Novartis PharmaceuticalsTerminatedRelapsing-remitting Multiple Sclerosis (RRMS)United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenCompletedFatigue | Relapsing-Remitting Multiple SclerosisSweden, Norway, Austria, Denmark
-
GE HealthcareCentre for Probe Development and CommercializationCompletedRelapsing-remitting Multiple Sclerosis (rrMS)Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | RRMSRussian Federation, Ukraine, Czech Republic
-
Universitätsklinikum Hamburg-EppendorfNeovii Biotech; Clinical Trial Center North (CTC North GmbH & Co. KG)TerminatedRelapsing-Remitting Multiple SclerosisGermany
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisCanada
-
BayerCompletedRelapsing-remitting Multiple SclerosisFrance
-
EMD SeronoWithdrawnRelapsing-Remitting Multiple Sclerosis
-
BiogenCompletedRelapsing-Remitting Multiple Sclerosis
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedMultiple Sclerosis (MS) - Relapsing-remittingUnited States
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsRecruitingRelapsing-Remitting Multiple SclerosisUnited States, Canada
-
Immunic AGActive, not recruitingRelapsing-Remitting Multiple Sclerosis (RRMS)Poland, Bulgaria, Romania, Ukraine
-
BiogenAbbVieTerminatedRelapsing-Remitting Multiple Sclerosis (RRMS)Italy, United States, Canada, Germany, Puerto Rico
-
BiogenElan PharmaceuticalsCompletedRelapsing Remitting Multiple Sclerosis (RRMS)Belgium, Mexico, Poland, Romania, Saudi Arabia, Ukraine
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States
-
EMD SeronoPfizerCompletedRelapsing Remitting Multiple Sclerosis (RRMS)United States
-
Charite University, Berlin, GermanyCompletedRelapsing-Remitting Multiple SclerosisGermany
-
Providence Multiple Sclerosis CenterBiogenCompletedClinically Isolated Syndrome | Relapsing-remitting Multiple SclerosisUnited States
-
University Hospital, CaenCompletedRelapsing-Remitting Multiple SclerosisFrance
-
Institut National de la Santé Et de la Recherche...UnknownMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited Kingdom, Ireland
-
Novartis PharmaceuticalsTerminatedRelapse Remitting Multiple SclerosisUnited States, Ukraine, Czechia
-
Imperial College LondonGlaxoSmithKline; University College, London; Medical Research Council; Queen Mary... and other collaboratorsCompletedRelapsing-remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
BayerCompletedRelapsing Remitting MS (RRMS) | Secondary Progressive MS (SPMS)France, Germany, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Czech Republic, Italy, Jordan, Lebanon, Turkey, Israel, Portugal, Netherlands, Iran, Islamic Republic of
-
Thomas Jefferson UniversityRecruitingRelapse Remitting Multiple SclerosisUnited States
-
BayerCompletedSecondary Progressive Multiple Sclerosis (SPMS) | Relapsing Remitting Multiple Sclerosis (RRMS)Portugal
-
Icahn School of Medicine at Mount SinaiWithdrawnRelapsing-remitting Multiple Sclerosis (RRMS)United States
-
Merck KGaA, Darmstadt, GermanyCompletedMultiple Sclerosis | Relapsing-RemittingSweden, Germany
-
University of MalagaUnknownRelapsing-remitting Multiple SclerosisSpain
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisPoland, Hungary, Turkey, Spain, Germany, United States, Canada, Switzerland, Russian Federation, Norway, Italy, Finland
-
Galapagos NVTerminatedClinically Isolated Syndrome | Acute Exacerbation of Remitting Relapsing Multiple SclerosisBelgium, Poland, Germany
-
Novartis PharmaceuticalsActive, not recruitingRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan